NASDAQ$IMCR

Immunocore Holdings plc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Headline financials

Total Revenue

$58M

Previous: $8.9M+552.1%
EPS (adj)

-$0.63

Previous: -$1.21+47.9%
Capital Expenditures

$2.2M

Previous: $1.39M+58.9%
Free Cash Flow

-$51.4M

Previous: -$144M+64.4%
Net Income

-$20.6M

Previous: -$16.1M-28.0%
Operating Income

-$21.5M

Previous: -$16.5M-30.6%
Gross Profit

$54.8M

Previous: $22.2M+146.7%
Cash & Equivalents

$402M

Previous: $321M+25.3%
Total Assets

$527M

No prior period
Stock-Based Comp

$32.9M

Previous: $48.9M-32.7%

Revenue & EPS history

Immunocore · Revenue · Quarterly

$58M

Q4 2022+552.1%vs Q4 2021
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-0.3%

Avg return

Earnings day

+0.9%

Avg return

5 days after

-1.2%

Avg return

30 days after

48%

10 / 21 earnings

Positive

+8.3%

Q3 2023

Best reaction

-11.0%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.6%+0.0%-2.1%
Q4 2025-4.8%-3.0%-12.6%
Q3 2025-3.2%+9.7%+21.5%
Q1 2025+6.3%+5.3%+32.8%
Q4 2024+5.3%-1.1%+1.3%
Q3 2024+4.0%+5.0%-4.5%
Q2 2024+0.8%+1.7%-9.5%
Q1 2024-1.9%-6.6%-31.7%
Q4 2023-4.6%-7.2%-7.7%
Q3 2023+8.3%+4.6%+15.8%
Q2 2023-3.3%-5.9%-12.7%
Q1 2023-1.5%+3.2%-4.6%
Q4 2022-4.9%-5.1%-9.9%
Q3 2022+2.9%+13.7%+9.3%
Q2 2022+1.6%+5.8%-13.5%
Q1 2022-11.0%+2.7%+1.4%
Q4 2021-0.7%+7.5%+37.7%
Q3 2021+0.4%-0.2%-21.3%
Q2 2021-4.9%-9.5%-1.4%
Q1 2021-1.5%-9.4%-5.3%
Q4 2020+0.1%+6.8%-7.1%
Q3 2020
Q2 2020
Q1 2020
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro